(a) Silencer Select: Life Technologies guarantees that when you purchase two Silencer Select Pre-designed siRNA to the same target, then those two siRNAs will silence the target mRNA by 70% or more. To qualify for the guarantee, siRNA's must have been transfected at ≥5 nM and mRNA levels detected 48h post transfection. Real-Time RT-PCR is recommended for this application. Customers must also show sufficient knockdown with a positive control siRNA to demonstrate transfection efficiency. If the guaranteed level of knockdown is not observed and an appropriate positive control is successful, a new Silencer Select siRNA sequence will be synthesized free of charge. This guarantee does not extend to any replacement product nor to siRNAs designed to silence lncRNAs.
(b) Stealth: Life Technologies guarantees that when you purchase three Stealth Pre-designed siRNA to the same target, then at least two of those three independent, non-overlapping siRNAs will silence the target mRNA by 70% or more. To qualify for the guarantee, siRNA's must have been transfected at ≥20 nM and mRNA levels detected 48h post transfection. Real-Time RT-PCR is recommended for this application. Customers must also show sufficient knockdown with a positive control siRNA to demonstrate transfection efficiency. If the guaranteed level of knockdown is not observed and an appropriate positive control is successful, a new Stealth siRNA sequence will be synthesized free of charge. This guarantee does not extend to any replacement product. We also recommend the use of an appropriate negative control, such as one of the three Stealth RNAi Negative Controls to normalize message knockdown.
(c) Silencer: Life Technologies guarantees that when you purchase three Silencer Pre−designed siRNAs to the same target, at least two of the siRNAs will reduce target mRNA levels in cultured cells by 70% or more when measured 48 hours after transfection at 100 nM or higher final siRNA concentration under the conditions described below. If at least two of the three siRNAs do not induce >70% target mRNA knockdown, Life Technologies will provide a one−time replacement of up to three Silencer Pre−designed siRNAs per target at no additional charge. Requests for replacement product must be made within one hundred and eighty (180) days from the date of delivery of the Silencer Pre−designed siRNAs. Optimum transfection efficiency must be confirmed using good laboratory practices and a proven−to−work siRNA to an endogenous message, such as Ambion Silencer GAPDH siRNA Control. To assess knockdown, target mRNA levels in treated samples must be compared to that of cells transfected with a nontargeting control siRNA, such as Silencer Negative Control #1. We recommend Applied Biosystems TaqMan Gene Expression Assays to quantify mRNA levels.
- Calandria et al (2015) NPD1-mediated stereoselective regulation of BIRC3 expression through cREL is decisive for neural cell survival, Cell Death and Differentiation, published online Jan 30.
- Bhinder B, Shum D, Li M, Ibanez G, Vlassov AV, et al. (2014) Discovery of a Dicer-Independent, Cell-Type Dependent Alternate Targeting Sequence Generator: Implications in Gene Silencing & Pooled RNAi Screens PLoS One 9:e100676.
- Vinod Udayar et al (2013) A Paired RNAi and RabGAP Overexpression Screen Identifies Rab11 as a Regulator of β-Amyloid Production Cell Reports 5:1552–1563.
- Virginie Buggia-Prévot et al (2013) A Function for EHD Family Proteins in Unidirectional Retrograde Dendritic Transport of BACE1 and Alzheimer's Disease Aβ Productio Cell Reports 5:1536–1551.
- Blattmann P1, Schuberth C, Pepperkok R, Runz H. (2013) RNAi-based functional profiling of loci from blood lipid genome-wide association studies identifies genes with cholesterol-regulatory function PLoS Genet 9:e1003338.
- Pau G, Walter T, Neumann B, Hériché JK, Ellenberg J, Huber W1 (2013) Dynamical modelling of phenotypes in a genome-wide RNAi live-cell imaging assay BMC Bioinformatics 14:308.
- Almaça J1, Faria D, Sousa M, Uliyakina I, Conrad C, Sirianant L, Clarke LA, Martins JP, Santos M, Heriché JK, Huber W, Schreiber R, Pepperkok R,Kunzelmann K, Amaral MD. (2013) High-content siRNA screen reveals global ENaC regulators and potential cystic fibrosis therapy targets Cell 154:1390–400.
- Szymborska A1, de Marco A, Daigle N, Cordes VC, Briggs JA, Ellenberg J. (2013) Nuclear pore scaffold structure analyzed by super-resolution microscopy and particle averaging Science. 9;341(6146):655–8.
- Stadler C, Hjelmare M, Neumann B, Jonasson K, Pepperkok R, Uhlén M, Lundberg E (2012) Systematic validation of antibody binding and protein subcellular localization using siRNA and confocal microscopy. Journal of Proteomics 75:2236-2251.
- Casanova CM1, Sehr P, Putzker K, Hentze MW, Neumann B, Duncan KE, Thoma C. (2012) Automated high-throughput RNAi screening in human cells combined with reporter mRNA transfection to identify novel regulators of translation PLoS One 7(9).
- Chrissie Y. Lee, Ronald L. Johnson, Jennifer Wichterman-Kouznetsova, Rajarshi Guha, Marc Ferrer, Pinar Tuzmen, Scott E. Martin, Wenge Zhu, Melvin L. DePamphilis (2012) High-throughput screening for genes that prevent excess DNA replication in human cells and for molecules that inhibit them Methods 57:234–248.
- Bo Rafn, Christian Friberg Nielsen, Sofie Hagel Andersen, Piotr Szyniarowski, Elisabeth Corcelle-Termeau, Erkka Valo, Nicole Fehrenbacher, Charlotta Johanne Olsen, Mads Daugaard, Christina Egebjerg, Trine Bøttzauw, Pekka Kohonen, Jesper Nylandsted, Sampsa Hautaniemi, Jose´ Moreira, Marja Jaattela, and Tuula Kallunki (2012) ErbB2-Driven Breast Cancer Cell Invasion Depends on a Complex Signaling Network Activating Myeloid Zinc Finger-1-Dependent Cathepsin B Expression Molecular Cell 45:764–776.
- Alexander V Sirotkin, Dmitriy Ovcharenko, and Milos Mlyncek (2010) Identification of protein kinases that control ovarian hormone release by selective siRNAs Journal of Molecular Endocrinology 44:45–53.
- Thomas Horn, Thomas Sandmann, and Michael Boutros (2010) Design and evaluation of genome-wide libraries for RNA interference screens Genome Biology 11:R61.
For Research Use Only. Not for use in diagnostic procedures.